Royalty Pharma Analyst Ratings
Royalty Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/11/2023 | 100.82% | Morgan Stanley | $53 → $54 | Maintains | Overweight |
| 08/09/2023 | 97.1% | Morgan Stanley | $52 → $53 | Maintains | Overweight |
| 07/11/2023 | 93.38% | Morgan Stanley | $52 → $52 | Reiterates | Overweight → Overweight |
| 05/10/2023 | 93.38% | Morgan Stanley | $50 → $52 | Maintains | Overweight |
| 04/10/2023 | 85.94% | Morgan Stanley | $48 → $50 | Maintains | Overweight |
| 04/06/2023 | 123.13% | Tigress Financial | $57 → $60 | Reiterates | → Buy |
| 02/16/2023 | 78.51% | UBS | $51 → $48 | Maintains | Buy |
| 12/06/2022 | 89.66% | Morgan Stanley | $54 → $51 | Maintains | Overweight |
| 11/09/2022 | 100.82% | Morgan Stanley | $51 → $54 | Maintains | Overweight |
| 10/18/2022 | 93.38% | JP Morgan | $50 → $52 | Maintains | Overweight |
| 08/08/2022 | 89.66% | Morgan Stanley | $48 → $51 | Maintains | Overweight |
| 07/14/2022 | 111.97% | Tigress Financial | $52 → $57 | Maintains | Buy |
| 06/14/2022 | 74.79% | UBS | → $47 | Initiates Coverage On | → Buy |
| 05/13/2022 | 97.1% | Scotiabank | → $53 | Initiates Coverage On | → Outperform |
| 04/27/2022 | 108.26% | Goldman Sachs | → $56 | Initiates Coverage On | → Buy |
| 04/14/2022 | 85.94% | JP Morgan | → $50 | Upgrades | Neutral → Overweight |
| 04/06/2022 | 78.51% | Morgan Stanley | $46 → $48 | Upgrades | Equal-Weight → Overweight |
| 10/29/2021 | 85.94% | Citigroup | → $50 | Upgrades | Neutral → Buy |
| 08/16/2021 | 71.07% | Morgan Stanley | $51 → $46 | Maintains | Equal-Weight |
| 07/30/2021 | 85.94% | Tigress Financial | → $50 | Initiates Coverage On | → Buy |
| 11/09/2020 | 89.66% | UBS | → $51 | Upgrades | Neutral → Buy |
| 07/13/2020 | 85.94% | JP Morgan | → $50 | Initiates Coverage On | → Neutral |
| 07/13/2020 | 104.54% | B of A Securities | → $55 | Initiates Coverage On | → Buy |
| 07/13/2020 | 89.66% | Morgan Stanley | → $51 | Initiates Coverage On | → Equal-Weight |
| 07/13/2020 | 104.54% | Cowen & Co. | → $55 | Initiates Coverage On | → Outperform |
| 07/13/2020 | 108.26% | SunTrust Robinson Humphrey | → $56 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月11日 | 100.82% | 摩根士丹利 | $53→$54 | 維護 | 超重 |
| 08/09/2023 | 97.1% | 摩根士丹利 | $52→$53 | 維護 | 超重 |
| 07/11/2023 | 93.38% | 摩根士丹利 | $52→$52 | 重申 | 超重→超重 |
| 2023年05月10日 | 93.38% | 摩根士丹利 | $50→$52 | 維護 | 超重 |
| 04/10/2023 | 85.94% | 摩根士丹利 | $48→$50 | 維護 | 超重 |
| 04/06/2023 | 123.13% | 虎妞金融 | $57→$60 | 重申 | →購買 |
| 02/16/2023 | 78.51% | 瑞銀集團 | $51→$48 | 維護 | 買 |
| 12/06/2022 | 89.66% | 摩根士丹利 | $54→$51 | 維護 | 超重 |
| 11/09/2022 | 100.82% | 摩根士丹利 | $51→$54 | 維護 | 超重 |
| 10/18/2022 | 93.38% | 摩根大通 | $50→$52 | 維護 | 超重 |
| 2022/08/08 | 89.66% | 摩根士丹利 | $48→$51 | 維護 | 超重 |
| 07/14/2022 | 111.97% | 虎妞金融 | $52→$57 | 維護 | 買 |
| 2022/06/14 | 74.79% | 瑞銀集團 | →$47 | 開始承保 | →購買 |
| 2022年05月13日 | 97.1% | 加拿大豐業銀行 | →$53 | 開始承保 | →跑贏大盤 |
| 04/27/2022 | 108.26% | 高盛 | →$56 | 開始承保 | →購買 |
| 04/14/2022 | 85.94% | 摩根大通 | →$50 | 升級 | 中性→超重 |
| 04/06/2022 | 78.51% | 摩根士丹利 | $46→$48 | 升級 | 等重→超重 |
| 10/29/2021 | 85.94% | 花旗集團 | →$50 | 升級 | 中性→購買 |
| 08/16/2021 | 71.07% | 摩根士丹利 | $51→$46 | 維護 | 等重 |
| 07/30/2021 | 85.94% | 虎妞金融 | →$50 | 開始承保 | →購買 |
| 11/09/2020 | 89.66% | 瑞銀集團 | →$51 | 升級 | 中性→購買 |
| 07/13/2020 | 85.94% | 摩根大通 | →$50 | 開始承保 | →中性 |
| 07/13/2020 | 104.54% | B of A證券 | →$55 | 開始承保 | →購買 |
| 07/13/2020 | 89.66% | 摩根士丹利 | →$51 | 開始承保 | →等重 |
| 07/13/2020 | 104.54% | 考恩公司 | →$55 | 開始承保 | →跑贏大盤 |
| 07/13/2020 | 108.26% | SunTrust Robinson Humphrey | →$56 | 開始承保 | →購買 |
What is the target price for Royalty Pharma (RPRX)?
Royalty Pharma(RPRX)的目標價是多少？
The latest price target for Royalty Pharma (NASDAQ: RPRX) was reported by Morgan Stanley on October 11, 2023. The analyst firm set a price target for $54.00 expecting RPRX to rise to within 12 months (a possible 100.82% upside). 10 analyst firms have reported ratings in the last year.
版稅醫藥(納斯達克：RPRX)的最新目標價是由摩根士丹利於2023年10月11日報道的。這家分析公司將目標價定為54美元，預計RPRX將在12個月內升至(可能上漲100.82%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Royalty Pharma (RPRX)?
Royalty Pharma(RPRX)的最新分析師評級是多少？
The latest analyst rating for Royalty Pharma (NASDAQ: RPRX) was provided by Morgan Stanley, and Royalty Pharma maintained their overweight rating.
王者醫藥(納斯達克股票代碼：RPRX)的最新分析師評級由摩根士丹利提供，皇室醫藥維持增持評級。
When is the next analyst rating going to be posted or updated for Royalty Pharma (RPRX)?
Royalty Pharma(RPRX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Royalty Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Royalty Pharma was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Royalty Pharma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Royalty Pharma的上一次評級是在2023年10月11日提交的，因此您應該預計下一次評級將在2024年10月11日左右提供。
Is the Analyst Rating Royalty Pharma (RPRX) correct?
分析師對Royalty Pharma(RPRX)的評級正確嗎？
While ratings are subjective and will change, the latest Royalty Pharma (RPRX) rating was a maintained with a price target of $53.00 to $54.00. The current price Royalty Pharma (RPRX) is trading at is $26.89, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Royalty Pharma(RPRX)評級維持不變，目標價在53.00美元至54.00美元之間。Royalty Pharma目前的交易價格為26.89美元，超出了分析師的預測區間。